Announcements
Excerpt from the Press Release: SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as…
Read More
Excerpt from the Press Release: SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Molecular Cancer Therapeutics, an American Association for Cancer Research journal, has selected as…
Read More
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic malignancies Follows ongoing clinical study of CLN-619 alone and in combination with pembrolizumab in solid tumors, with anticipated updated clinical data in Q2 2024 Excerpt from the Press Release: CAMBRIDGE, Mass., March 01, 2024…
Read More
Matching adjusted indirect comparison addresses key questions and limitations associated with previously presented analysis and suggests efficacy advantage of BRUKINSA vs acalabrutinib Excerpt from the Press Release: BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new matching adjusted indirect comparison (MAIC)…
Read More
– New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients – – Company discontinued the ONSEMBLE trial in August 2023 to shift focus of clinical development program to first-line RAS-mutated mCRC in agreement with the FDA – Excerpt…
Read More
– A-005 is a potential first-in-class, brain penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases –– Data support planned Phase 1 clinical trial on track to initiate in 1H 2024 – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 1, 2024 – Alumis Inc., a clinical-stage biopharmaceutical company developing oral…
Read More
Excerpt from the Press Release: WILMINGTON, Mass. & OKLAHOMA CITY–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) today announced a strategic agreement with Wheeler Bio, Inc., an antibody contract development and manufacturing organization (CDMO) focused on preclinical and early clinical supply of recombinant proteins, providing clients access to Wheeler’s Portable CMC® (Chemistry, Manufacturing and Controls)…
Read More Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on: Excerpt from the Press Release: WALTHAM, Mass. and BOULDER, Colo., Feb. 22, 2024 (GLOBE NEWSWIRE) — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today…
Read More
Excerpt from the Press Release: MALVERN, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the first cohort of its Phase 1/2 GARDian clinical trial for…
Read More
Excerpt from the Press Release: WAYNE, Pa.–(BUSINESS WIRE)–Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product’s status following the previously announced proof of concept results based on the 12-week data in January 2024. The latest data…
Read More